Paul Kessler
Keine laufenden Positionen mehr
Profil
Paul Kessler worked as an Executive Director of Clinical Research at GenVec, Inc. from 1998 to 2005.
He then worked as a Senior VP of Clinical, Medical & Regulatory Affairs at Nabi Biopharmaceuticals from 2005 to 2012.
Dr. Kessler holds a doctorate degree from The Trustees of Columbia University in The City of New York, an undergraduate degree from the University of Pittsburgh, and a graduate degree from the University of London.
Ehemalige bekannte Positionen von Paul Kessler
| Unternehmen | Position | Ende |
|---|---|---|
Nabi Biopharmaceuticals
 Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | Technik-/Wissenschafts-/F&E-Leiter | 05.08.2012 |
| GENVEC INC | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2005 |
Ausbildung von Paul Kessler
| University of Pittsburgh | Undergraduate Degree |
| University of London | Graduate Degree |
| The Trustees of Columbia University in The City of New York | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | Health Technology |
GenVec, Inc.
 GenVec, Inc. Pharmaceuticals: MajorHealth Technology GenVec, Inc. operated as a clinical-stage gene delivery company, which engaged in the development of therapeutics and vaccines. The firm designs, tests, and manufactured adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products included CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and was headquartered in Rockville, MD. | Health Technology |
